Results 111 to 120 of about 8,790,513 (336)

Costs and effectiveness for the two comparator scenarios, with their incremental differences and the incremental cost-effectiveness ratio (ICER).

Costs and effectiveness for the two comparator scenarios, with their incremental differences and the incremental cost-effectiveness ratio (ICER).
Doruk Ozgediz (252061), Maija Cheung (18264948), Emmanuel A. Ameh (3281115), Ruth Laverde (18264939), Paul Park (3441032), Ava Yap (18264933), Nancy Ukwu (9020855), Elliot Marseille (54691), Salamatu I. Halid (18264936), Greg Klazura (18264942), Emma Bryce (18264945)   +10 more
core   +1 more source

Cost effectiveness ratio and incremental cost effectiveness ratio analysis per year and period considering the cost of embedded pharmaceutical care in the cost of the public health system with assistance to hypertensive patients.

, 2018
Cost effectiveness ratio and incremental cost effectiveness ratio analysis per year and period considering the cost of embedded pharmaceutical care in the cost of the public health system with assistance to hypertensive patients.
Maurílio de Souza Cazarim (2838158), Leonardo Régis Leira Pereira (492901)   +1 more
core   +1 more source

Monolithic Oxidation Enables Ultrathin Vertically Graded Tantalum Oxide for Low‐Voltage, Low‐Variability Memristive Switching

Advanced Functional Materials, EarlyView.
Monolithic UV‐ozone oxidation of Ta forms an ultrathin Ta2O5/TaOx bilayer enabling resistive switching with a vertical defect gradient. A stoichiometric surface layer over an oxygen‐deficient sublayer promotes localized filament nucleation near the top interface, enabling low‐voltage operation, and reduced cycle‐to‐cycle variability.
Seunghoon Yang, Dong Hyun Lee, Conan Weiland, Won‐Il Lee, Kim Kisslinger, Mingzhao Liu, Aswin kumar Anbalagan, Xiao Tong, Soumyajit Mandal, Nikhil Tiwale, Houk Jang, Chang‐Yong Nam   +11 more
wiley   +1 more source

Cost-effectiveness acceptability curve from a 1,000 cohort simulation.

, 2019
The acceptability curve represents the likely of TDM being accepted depending on the price of imatinib at varying levels of willingness-to-pay threshold.
Philip S. Bernard (8173509), Srinivas Tantravahi (8173512), Gwendolyn A. McMillin (8173506), Robert L. Schmidt (8173518), Kibum Kim (1420720), Brandon S. Walker (8173515)   +5 more
core   +1 more source

Gradient‐Conductivity Architecture Enables Synchronous Enhancement of Sensitivity and Detection Range in Multifunctional All‐Paper Sensors

Advanced Functional Materials, EarlyView.
A gradient‐engineered all‐paper sensor is fabricated by integrating MXene and in situ grown AgNPs within hierarchical cellulose networks. The device breaks the sensitivity–detection range trade‐off through cascaded conductive pathways, enabling ultrahigh pressure sensitivity, humidity–pressure decoupled dual‐mode sensing, and outstanding EMI shielding,
Ao Li, Jun Xu, Dezhong Xu, Zhaohui Zhang, Jiyi Li, Daxian Cao, Kefu Chen, Mizi Fan   +7 more
wiley   +1 more source

Effectiveness of Diabetes Mellitus Type 2 Management in Prolanis Participants at the BPJS Kesehatan Sibolga

Jurnal Jaminan Kesehatan Nasional
BPJS Kesehatan aims to improve the health of participants suffering from Type 2 DM through the Chronic Disease Management Program “Prolanis” (Program Pengelolaan Penyakit Kronis) strategy implemented at Primary Health Care (PHC).
ester sitompul, Firdaus Hafidz As Shidieq   +1 more
doaj   +1 more source

Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in USA.

Immunotherapy, 2019
Aim: This analysis aimed to evaluate the cost-effectiveness of pembrolizumab monotherapy as first-line treatment in advanced non-small-cell lung cancer patients with a programmed death ligand 1 (PD-L1) tumor proportion score ≥1% from a US payer ...
Min Huang, G. de Lima Lopes, R. Insinga, T. Burke, F. Ejzykowicz, Ying Zhang, J. Feliciano   +6 more
semanticscholar   +1 more source

Cost-effectiveness plane.

Abbreviations: DALYs, disability-adjusted life years; ICER, incremental cost-effectiveness ratio.
Winfrida Mdewa (17935437), Evelyn Thsehla (13759703), Susan Goldstein (15264632), Aisha Moolla (17935434), Agnes Erzse (11559477), Ciaran Kohli-Lynch (5467187), Karen Hofman (752510)   +6 more
core   +1 more source

Incremental Cost-effectiveness Ratios from the Societal Perspective Referencing PCF as a Common Baseline.

, 2015
a: Effectiveness are rounded to the nearest whole number per 1000 person screened in the target populationb: ICER- Incremental Cost-Effectiveness Ratio (incremental cost divided by incremental effectiveness)*calculations of ICERs do not exactly match ...
Kevin Dobbin (2864), James Oloya (690419), Phaedra S. Corso (690420), Juliet N. Sekandi (690418), Christopher C. Whalen (116033), Alphonse Okwera (227454)   +5 more
core   +1 more source

Incremental cost-effectiveness.

, 2022
Incremental cost-effectiveness.
Kwaku Appiah-Korang Labi (12197339), Ama Pokuaa Fenny (12197333), Evans Otieku (12197336), Ulrika Enemark (6987809), Felix Ankomah Asante (7309928)   +4 more
core   +1 more source